Johnson & Johnson (NYSE:JNJ) Sets New 12-Month High – Here’s What Happened

Shares of Johnson & Johnson (NYSE:JNJ) reached a new 52-week high on Wednesday . The company traded as high as $269.43 and last traded at $267.3470, with a volume of 9074553 shares. The stock had previously closed at $259.33.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson received FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform, a new ablation catheter platform that could strengthen its electrophysiology business and help drive future growth. Article Title
• Positive Sentiment: Jim Cramer said Johnson & Johnson “will have lots of good news” about its blockbuster drugs, adding to bullish sentiment around the stock. Article Title
• Positive Sentiment: Zacks highlighted JNJ’s strong earnings surprise history and said the company has the ingredients to beat estimates again in its next quarterly report, reinforcing confidence ahead of earnings. Article Title
• Positive Sentiment: TipRanks included Johnson & Johnson among Dividend Aristocrat stocks with a “Strong Buy” rating from top analysts, which may support demand for the shares. Article Title
• Neutral Sentiment: Several broader healthcare and market commentary pieces referenced JNJ as a defensive Dividend Aristocrat, but these were mostly general background items rather than company-specific catalysts. Article Title
• Negative Sentiment: Recent coverage also noted that JNJ had slipped in the prior session, suggesting some near-term profit-taking even as longer-term fundamentals remain intact. Article Title

Analysts Set New Price Targets

JNJ has been the subject of several recent research reports. Wells Fargo & Company upped their price target on Johnson & Johnson from $240.00 to $263.00 and gave the company an “overweight” rating in a report on Wednesday, April 15th. Leerink Partners raised Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 price objective on the stock in a report on Wednesday, May 13th. Stifel Nicolaus upped their target price on Johnson & Johnson from $220.00 to $250.00 and gave the company a “hold” rating in a research note on Wednesday, April 15th. Weiss Ratings cut Johnson & Johnson from a “buy (b)” rating to a “buy (b-)” rating in a research report on Monday, June 15th. Finally, Barclays lifted their price target on shares of Johnson & Johnson from $234.00 to $255.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 15th. Twenty investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $257.74.

Johnson & Johnson Stock Down 1.9%

The stock has a market capitalization of $622.22 billion, a price-to-earnings ratio of 29.88, a price-to-earnings-growth ratio of 2.58 and a beta of 0.24. The firm has a 50 day simple moving average of $236.47 and a 200-day simple moving average of $232.88. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, beating the consensus estimate of $2.68 by $0.02. The company had revenue of $24.06 billion for the quarter, compared to the consensus estimate of $23.60 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The firm’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, sell-side analysts forecast that Johnson & Johnson will post 11.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were paid a dividend of $1.34 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend was Tuesday, May 26th. Johnson & Johnson’s payout ratio is currently 61.97%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the sale, the executive vice president owned 114,288 shares of the company’s stock, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Johnson & Johnson

Several institutional investors have recently bought and sold shares of the business. Sierra Capital LLC grew its holdings in Johnson & Johnson by 0.5% during the 4th quarter. Sierra Capital LLC now owns 8,144 shares of the company’s stock worth $1,685,000 after acquiring an additional 41 shares during the last quarter. Beaird Harris Wealth Management LLC lifted its position in shares of Johnson & Johnson by 1.8% during the fourth quarter. Beaird Harris Wealth Management LLC now owns 2,422 shares of the company’s stock worth $501,000 after purchasing an additional 42 shares in the last quarter. Ballast Advisors LLC lifted its position in shares of Johnson & Johnson by 1.2% during the first quarter. Ballast Advisors LLC now owns 3,598 shares of the company’s stock worth $879,000 after purchasing an additional 42 shares in the last quarter. Broadleaf Partners LLC grew its stake in shares of Johnson & Johnson by 0.6% during the fourth quarter. Broadleaf Partners LLC now owns 7,348 shares of the company’s stock valued at $1,521,000 after purchasing an additional 43 shares during the last quarter. Finally, Jessup Wealth Management Inc increased its holdings in shares of Johnson & Johnson by 0.6% in the fourth quarter. Jessup Wealth Management Inc now owns 7,574 shares of the company’s stock valued at $1,567,000 after purchasing an additional 44 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.